Raltegravir 600 mg once daily

Sue Dickinson, Director of Pharmacy, Regional Drug & Therapeutics Centre (Newcastle)Published

Raltegravir (Isentress®) is an integrase strand transfer inhibitor licensed in combination with other antiretroviral drugs for the treatment of Human Immunodeficiency Type 1 (HIV-1) infection. A once-daily 600 mg tablet formulation of raltegravir was recently launched in the UK in order to reduce the pill burden and offer a more convenient treatment option. This bulletin reviews the new once-daily raltegravir 1200 mg regimen (two 600 mg tablets taken once-daily) and compares this to the existing 400 mg twice-daily regimen.